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Abstract
The validation of candidate biomarkers often is hampered by the lack of a reliable means of
assessing and comparing performance. We present here a reference set of serum and
plasma samples to facilitate the validation of biomarkers for resectable pancreatic cancer.
The reference set includes a large cohort of stage I-II pancreatic cancer patients, recruited
from 5 different institutions, and relevant control groups. We characterized the performance
of the current best serological biomarker for pancreatic cancer, CA 19–9, using plasma
samples from the reference set to provide a benchmark for future biomarker studies and to
further our knowledge of CA 19–9 in early-stage pancreatic cancer and the control groups.
CA 19–9 distinguished pancreatic cancers from the healthy and chronic pancreatitis groups
with an average sensitivity and specificity of 70–74%, similar to previous studies using all
stages of pancreatic cancer. Chronic pancreatitis patients did not show CA 19–9 elevations,
but patients with benign biliary obstruction had elevations nearly as high as the cancer
patients. We gained additional information about the biomarker by comparing two distinct
assays. The two CA 9–9 assays agreed well in overall performance but diverged in mea-
surements of individual samples, potentially due to subtle differences in antibody specificity
as revealed by glycan array analysis. Thus, the reference set promises be a valuable
resource for biomarker validation and comparison, and the CA 19–9 data presented here
will be useful for benchmarking and for exploring relationships to CA 19–9.
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Introduction
Advances in knowledge about pancreatic cancer have generated enthusiasm about the pros-
pects for significant progress against this deadly disease [1, 2]. Among other areas, the field has
witnessed advances in understanding the genetic initiation and progression of the disease [3],
the role of the stroma in promoting cancer and in obstructing systemic therapies [4–7], and the
role of plasticity in the cancer cell [8]. While this information will be foundational in the devel-
opment of effective therapies, improvements in survival also will depend on better detection,
diagnostics, and treatment decisions based on individual patient characteristics. We need to
advance our ability to detect a pancreatic cancer at an early stage, when it is potentially curable
by surgical resection, and we need better ways to determine the route of care that will be most
effective for each patient.
Molecular biomarkers promise to provide such precise, patient-specific information [9], but
their development and implementation is challenging and slow. In pancreatic cancer research,
a major bottleneck for the development of molecular biomarkers is the limited resources for
assessing and comparing candidate biomarkers using samples collected at early stages of cancer
development, when resection for cure is possible. A significant amount of time usually is
required before an accurate assessment of a biomarker is possible and before decisions about
further investment can be made. More often than not, promising results in early studies are not
substantiated in follow up studies, or the performance of a biomarker is not consistent between
studies [10, 11]. A consistent and systematic approach to evaluating candidate biomarkers is
required.
To address the need for the evaluation of pancreatic cancer biomarkers, a collaborative
group within the Early Detection Research Network (EDRN) recently developed a reference set
of human specimens. The motivation for developing the reference set was to enable definitive
evaluation of candidate biomarkers for pancreatic cancer, to provide accurate comparisons
between candidate biomarkers, and to test the combined use of disparate biomarkers. A com-
mon set of specimens, collected under rigorous standards at multiple institutions and compris-
ing the patient populations most relevant to the clinical requirements, is necessary for
achieving these goals [12]. Several principles guided the creation of the set. The set was to
include samples from multiple institutions, so that it is not representative of only one geo-
graphical area; sample collection was to follow a single, detailed standard operating procedure,
to prevent the introduction of bias into the set; the patients were to include many with resect-
able cancer, which is the most difficult to detect yet the most important for potential positive
impact; and the control subjects were to include both healthy people and patients with benign
conditions of the pancreas, because certain benign conditions can be hard to distinguish from
pancreatic cancer and could cause elevations in cancer biomarkers.
Regarding the patient population, we chose to assemble samples from patients with stage I
or II cancer as confirmed by surgical pathology. Such patients are eligible for surgical treatment
and on average have significantly better outcomes than the rest of pancreatic cancer patients.
Detecting cancer even earlier, i.e. at carcinoma in-situ or PanIN–3, would be preferable to
detection at stage I because patients with stage I typically still develop recurrence after surgery.
At present we do not have a way to routinely confirm the presence of PanIN–3, so assembling
samples from a cohort of such patients is not yet possible. An alternate approach used previ-
ously was to assemble samples that had been collected prior to the diagnosis of pancreatic can-
cer, identified through the examination of follow-up information from massive public-health
studies to find subjects who eventually developed pancreatic cancer [13, 14]. Such samples are
precious for exploring the feasibility of screening for cancer, but they are not designed to test
for detection prior to stage I or II because the stage of disease is not known. In addition,
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because of the difficulty in obtaining such samples, they normally are persevered for only a
small number of studies. Therefore we pursued the assembly of a sample set that could be used
for many studies and that would be relevant to an important goal in pancreatic cancer treat-
ment, the detection of more cancers at a stage that is eligible for surgery.
The CA 19–9 assay is the current best serological biomarker for pancreatic cancer. The CA
19–9 monoclonal antibody was raised against a colorectal cancer cell line [15], and the antigen
it binds is a carbohydrate structure attached to a variety of proteins and lipids [16]. Although
its blood levels are strongly associated with pancreatic cancer—it is elevated in 70–80% of pan-
creatic cancer patients and in about 20% of patients with benign conditions of the pancreas
[17]—its performance is not sufficient for diagnosing cancer, as the risk of both false negative
and false positive diagnoses is unacceptably high. About 5% of pancreatic cancer patients do
not elevate CA 19–9 due to germline mutations resulting in inability to produce the glycan
[18], and another group of patients do not elevate CA 19–9 for unknown reasons. The non-
specific elevations in CA 19–9 result mainly from damage to the bile duct or portions of the
pancreatic ducts that are coated with the CA 19–9 antigen. New biomarkers for the diagnosis
of resectable cancer must perform better than CA 19–9, both in sensitivity and specificity,
either as a single biomarker or more likely in combination.
The goals of the present study were to 1) determine the performance of CA 19–9 in the ref-
erence set; 2) more clearly define the performance of CA 19–9 for stage I-II disease and in ref-
erence to the potentially confounding conditions of benign biliary obstruction and chronic
pancreatitis; and 3) compare the performance and define the origins of differences between dis-
tinct CA 19–9 assays. The first goal was necessary to give a benchmark by which we can com-
pare and evaluate candidate biomarkers. The second goal was necessary because many of the
previous studies of CA 19–9 were heavily weighted toward late-stage cancer, mainly because
samples from late-stage cancer patients are more readily available. Patients with stage I-II dis-
ease have the potential for improved outcomes through surgery, so the accurate and early
detection of this level of disease is critically important. The third goal was necessary because
the previous studies of CA 19–9 in pancreatic cancer have divergent results, likely owing to dif-
ferences in the specificities of the antibodies [19] or differences in the assay platforms. It is
important to understand the implications of these differences for decisions for individual
patients. In addition, more information about the glycans bound by each CA 19–9 antibody
potentially would help to characterize the glycans produced by cancer patients and to formu-
late strategies for detecting a greater percentage of patients than possible now.
Materials and Methods
Eligibility criteria
Each site conducted sample collection using a protocol and written consent form that were
approval by their Institutional Review Board. Subjects were required to provide written,
informed consent. The sites participating in the sample collection were the University of Pitts-
burgh Medical Center, Memorial Sloan Kettering Cancer Center, the University of Michigan,
the University of Nebraska, and Northshore University Healthsystem (previously known as
Evanston Northwestern Healthcare). The following inclusion criteria were required for pancre-
atic cancer cases and controls. The control groups included chronic pancreatitis patients, acute
benign biliary obstruction patients, and healthy subjects.
Pancreatic cancer cases.
1. Subjects underwent curative pancreatic resection for an adenocarcinoma including negative
margins and preferably Stage 1 or 2A (absence of lymph node metastases).
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2. No prior history of any other malignancy except nonmelanoma skin cancers for ten years.
Chronic pancreatitis cases.
1. All subjects must have had at least two of the radiological criteria listed below, unless a sub-
ject had a history of pancreatic exocrine insufficiency, in which case only one radiological
criterion was required.
a. Abdominal ultrasound that is consistent with chronic pancreatitis by standard radiologi-
cal criteria
b. Abdominal CT scan consistent with chronic pancreatitis by standard radiological criteria
(i.e., calcifications, dilated pancreatic duct, irregular contour of the gland, cystic lesions).
c. Endoscopic retrograde cholangiopancreatography (ERCP) exam consistent with chronic
pancreatitis by standard radiological criteria (dilated tortuous main pancreatic duct with
irregular secondary branches, intraductal calculi).
d. Endoscopic ultrasound consistent with chronic pancreatitis by standard sonographic
criteria.
e. Pancreatic calcifications identified on plain film of the abdomen.
2. All subjects had an imaging study of the pancreas within 3 months of study enrollment
which did not suggest a pancreatic mass.
3. All subjects had a stable clinical history over the past year with no suspicion for cancer
(weight loss, jaundice, or change in abdominal symptoms).
4. All subjects had no prior history of any other malignancy except non-melanoma skin can-
cers for the past ten years.
5. All subjects had no family history of pancreatic cancer.
Acute benign biliary obstruction cases.
1. All subjects met all of the following clinical criteria:
a. Elevation of serum bilirubin level greater than 2.0 mg/dL
b. Dilated extrahepatic biliary systems demonstrated on imaging study
c. Blood sample obtained prior to any corrective intervention.
2. All subjects had biliary obstruction that was of benign etiology such as common bile duct
stone or benign biliary stricture.
3. Patients with primary sclerosing cholangitis (PSC) were excluded.
4. All subjects had a complete imaging study performed of the pancreas that did not suggest a
pancreatic cancer, such as a discrete mass lesion.
5. All subjects had no prior history of any other malignancy except non melanoma skin can-
cers for the past ten years.
6. All subjects had no family history of pancreatic cancer.
CA 19-9 in the Pancreatic Reference Set
PLOS ONE | DOI:10.1371/journal.pone.0139049 October 2, 2015 4 / 18
Healthy controls. All subjects met the following criteria.
1. Age, race and sex matched to qualified pancreatic cancer cases.
2. No family history of pancreatic cancer.
3. No personal history of acute pancreatitis or biliary obstruction as defined above.
4. No concurrent abdominal pain.
5. No concurrent unexplained weight loss.
6. No prior history of any other malignancy except non-melanoma skin cancers for the past
ten years.
There was no extended follow up beyond the time that the samples were sent at the end of
the collection period. While the possibility exists that one or more of the controls had incipient
cancer at the time of sample collection, the effect on the study likely would be negligible. Due
to how rare the disease is in the general population with a life-time risk of 1 in 71 patients, it
would only be anticipated that at most one of these patients at a general population risk for PC
will ever develop a cancer in their life-time.
Serum and plasma collection
All collections took place following informed consent of the participants and prior to any sur-
geries or procedures. The samples were collected from February 21, 2005 to April 20, 2011, and
the experiments were performed in 2013 and 2014. All blood samples were collected according
to the EDRN standard operating procedure. All samples were frozen at -70°C or colder within
4 hours of time of collection. Four mL of serum and 2 mL of plasma (using EDTA as the anti-
coagulant) were shipped from participating sites to NCI Biorepository in Frederick, Maryland.
The specimens were transferred to the repository in a manner that prevented thawing using
approved transporter techniques. Aliquots were sent on dry ice to the sites performing the CA
19–9 analyses, and no aliquots were thawed more than three times total prior to use.
The healthy controls were collected from 4 out of the 5 sites with contributions of the con-
trols matching the overall contributions from each site (Table 1). We monitored the control
recruitment to ensure there was reasonable matching of the controls to the cases in age, race,
and sex, but we relaxed the algorithm somewhat with the chronic pancreatitis patients owing
to the earlier age of onset relative to pancreatic cancer.
Definitions of tumor stages
The pancreatic adenocarcinomas were staged according to the criteria in the American Joint
Committee on Cancer (AJCC) Staging Manual 7th edition. The following definitions of tumor
extent and nodal status were used: T1 = Tumor limited to the pancreas2 cm in greatest
dimension; T2 = Tumor limited to the pancreas>2 cm in greatest dimension; T3 = Tumor
extends beyond the pancreas but without involvement of the celiac axis or the superior mesen-
teric artery; N0 = No regional lymph node metastasis; and N1 = Regional lymph node metasta-
sis. The stages were defined as: Stage 1a = T1N0M0; Stage 1b = T2N0M0; Stage 2a = T3N0M0;
and Stage 2b = T1-3N1M0.
CA 19–9 assays
Two laboratories ran CA 19–9 assays on aliquots of the plasma samples that were received
without any identifying information. One assay, the EIA–1474 kit [Lot #RN–45868] from
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DRG International (Springfield, NJ), was run in the laboratory of Dr. Killary according to pre-
viously published methods [20]. The other assay was developed and run in the laboratory of
Dr. Haab using a previously published protocol [19, 21, 22]. In the subsequent text, we refer to
the former as “Assay 1” and the latter as “Assay 2.” The DRG kit nominally is approved only
for serum, but it previously was used for plasma to achieve results similar to those achieved
using serum [20]. In this study, we further validated its use with plasma by confirming statisti-
cal equivalence with Assay 1 and with the Abbott Architect platform (see Results). A subset of
the samples (n = 82) was analyzed using the CA 19–9 assay on the Abbott Architect Immuno-
assay platform at the University Health Network in Toronto, Canada. See the S1 File for addi-
tional information about the protocols and assay characteristics.
Table 1. Characteristics of study subjects.
Healthy
control
(N = 61)
Chronic
pancreatitis
(N = 62)
Acute
benign
biliary
obstruction
(N = 31)
Pancreatic
cancer
(N = 98)
Total
(N = 252)
N % N % N % N % N %
Centers
ENH 0 (0%) 0 (0%) 0 (0%) 15 (15%) 15 (6%)
MSKCC 9 (15%) 0 (0%) 0 (0%) 24 (25%) 33 (13%)
Pitt 26 (43%) 36 (58%) 14 (45%) 26 (27%) 102 (40%)
UMHS 12 (20%) 22 (35%) 16 (52%) 19 (19%) 69 (27%)
UNMC 14 (23%) 4 (6%) 1 (3%) 14 (14%) 33 (14%)
Ages
<50 1 (2%) 7 (11%) 3 (10%) 1 (1%) 12 (5%)
50~59 19 (31%) 24 (39%) 6 (19%) 13 (13%) 62 (25%)
60~69 25 (41%) 17 (27%) 10 (32%) 35 (36%) 87 (35%)
70~79 10 (16%) 12 (19%) 7 (23%) 29 (39%) 58 (23%)
>80 6 (10%) 2 (3%) 5 (16%) 20 (21%) 33 (13%)
Gender
Male 25 (41%) 36 (56%) 12 (39%) 43 (44%) 116 (46%)
Female 36 (59%) 26 (44%) 19 (61%) 55 (56%) 136 (54%)
Race
White 55 (90%) 57 (92%) 29 (94%) 89 (92%) 230 (91%)
Asian 0 (0%) 0 (0%) 0 (0%) 3 (3%) 3 (1%)
African-American 6 (10%) 4 (6%) 2 (6%) 1 (1%) 13 (5%)
Native and others 0 (0%) 1 (2%) 0 (0%) 5 (4%) 6 (2%)
Tumor Stages
IA 7 (7%)
IB 8 (8%)
II 1 (1%)
IIA 40 (41%)
IIB 42 (43%)
ENH, Evanston Northwestern Healthcare; MSKCC, Memorial Sloan Kettering Cancer Center; Pitt,
University of Pittsburgh Medical Center; UMHS, University of Michigan Health Services; UNMC, University
of Nebraska Medical Center.
doi:10.1371/journal.pone.0139049.t001
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Statistical analysis
For each group, we compared the CA19-9 distributions between the two CA19-9 assays using
the paired t-test (on log-transformed CA19-9) and the Wilcoxon Signed Rank test. The Spear-
man rank correlation coefficient between the two assays was also computed. For descriptive
analyses, we generated a boxplot for each CA19-9 assay and each group; the geometric means
of individual assays and their 95%Wald confidence intervals also were computed.
For pairwise comparisons among the healthy, benign biliary obstruction, chronic pancreati-
tis, and cancer groups, we performed two-sample t-tests (on the log-transformed CA19-9 val-
ues) and the Wilcoxon Rank Sum tests. In addition, for each paired control and case group, we
generated a nonparametric estimate of the receiving operating characteristics (ROC) curve
[23] and the area-under-the-curve (AUC) for the individual CA19-9 assays and for a linear
combination of the log-transformed values from the two assays derived from logistic regression
models. The bootstrap procedure with 500-fold resampling was used for constructing the con-
fidence intervals of the AUCs of the individual assays, of the differences in AUC between the
two CA19-9 assays, and of the difference in AUC between the individual CA19-9 assays and
the combined assays.
For the individual CA19-9 assays, we examined the sensitivities and specificities using the
clinical cutoff of 37 U/mL as well as a derived cutoff that maximizes the sum of sensitivity and
specificity. We also estimated sensitivity and specificity based on combinations of the two
CA19-9 assays using AND/OR rules. The bootstrap procedure with 500-fold resampling was
used for constructing the confidence intervals for sensitivity, specificity, and the sum of sensi-
tivity and specificity.
Glycan array experiments and analysis
The core laboratory for Glycan Array Synthesis (part of the Consortium for Functional Glyco-
mics, CFG) at Emory University performed the glycan array experiments and primary analy-
ses. The array version used here was 5.1, containing 610 unique glycans. The experiments
followed published protocols [24]. We used the program GlycoSearch [25] to analyze the gly-
can array data.
Results
CA 19–9 in the reference set
The reference set included serum and plasma samples collected at five different institutions
under a common standard operating procedure. The samples are from 98 patients with stage
I-II pancreatic cancer, 62 patients with chronic pancreatitis, 31 patients with benign biliary
obstruction, and 61 healthy control subjects (Table 1).
We determined the CA 19–9 values in the plasma samples using two different assays, one a
commercially-available kit (referred to as Assay 1), and the other an in-house system (referred
to as Assay 2). We used two different assays in order to account for potential differences
between assays, given previous observations of such differences [26, 27]. We tested the reliabil-
ity the assays used here by comparisons with an automated platform (Abbott Architect CA 19–
9 Immunoassay) for 82 of the samples distributed across the patient groups. The values within
each of the patient groups were statistically equivalent between all three assays, except for
slightly higher levels among healthy controls for Assay 2 relative to the Abbott assay (Table A1
in S3 File), and the discrimination of cancer from the control groups was statistically equivalent
between all assays (Table B in S3 File and S1 File). This result confirms the reliability of the
results obtained using Assays 1 and 2 and their general equivalence with automated platforms.
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We first examined the distributions of the values for each of the assays in the various patient
groups (Fig 1A). The healthy subjects and chronic pancreatitis patients had the lowest levels;
benign biliary obstruction patients had significantly higher levels (p-value is less than 0.0001
Fig 1. Differentiating pancreatic cancer from control subjects by two different CA 19–9 assays. A) CA 19–9 levels in each group. We present the log-
transformed values to better visualize all ranges of the values. The boxes indicate the quartiles of the distributions, the horizontal lines in the boxes indicate
the medians, and the dashed lines give the ranges, with individual outliers indicated by the circles. A1, Assay 1; A2, Assay 2. B-D) Receiver-operator-
characteristic (ROC) curves comparing all pancreatic cancer patients to the indicated control groups. The legends specify the area-under-the-curves (AUCs)
for each assay, with the ranges of the 95% confidence intervals.
doi:10.1371/journal.pone.0139049.g001
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and equal to 0.006 by Wilcoxon Rank Sum test, relative to healthy subjects for Assay 1 and 2
respectively); and cancer patients had the highest levels (p<0.0001 relative to healthy subjects
based on either t-test or Wilcoxon Rank Sum test for each assay). The two assays showed
equivalent trends. Detailed results about the geometric means of the individual assays and their
95% confidence intervals are presented in Table C in S3 File, and the p-values for the compari-
sons between patient groups are presented in Table D in S3 File.
We asked whether the CA 19–9 levels were different between the earlier-stage (stages Ia, Ib,
and IIa) and the later-stage (stage IIb) patients. The CA19-9 levels were not significantly different
between the two groups (p-values based on t-test andWilcoxon Rank Sum test); and the area-
under-the-curve (AUC) values in receiver-operating-characteristic (ROC) analysis also were not
statistically significantly different between the groups for the differentiation of cancer from healthy
subjects (S2 File). Therefore in the subsequent analyses we grouped all cancer patients together.
We used the AUC to determine the ability of CA 19–9 to distinguish the groups. The CA19-9
assays were best at separating the cancer from healthy control groups (AUCs equal to 0.78 with
95% CI (0.70,0.84) for Assay 1, and 0.76 (0.68, 0.83) for Assay 2) (Fig 1B). The assays also had
good performance in separating the cancer from chronic pancreatitis groups (AUCs equal to 0.73
with 95% CI (0.65, 0.80) for Assay 1, and 0.77 (0.69, 0.83) for Assay 2) (Fig 1C), but they were not
effective at separating the cancer from the benign biliary obstruction groups (AUCs equal to 0.56
with 95% CI (0.47, 0.67) for Assay 1, and 0.62 (0.45, 0.71) for Assay 2) (Fig 1D). There were no
statistically significant differences in AUCs between Assays 1 and 2 in each of these comparisons.
To more directly relate these results to clinical practice, we examined the sensitivities and
specificities of the CA19-9 assays at the typical cutoff used in practice, 37 U/mL, and at cutoffs
that gave maximum sums of sensitivity and specificity (Table 2). At the 37 U/mL cutoff, the
average of the sensitivity plus specificity ranged from 70 to 74 for the discrimination of cancer
from the healthy and chronic pancreatitis control groups. For both assays, a lower threshold
greatly increased sensitivity with a lesser decrease in specificity, resulting in a statistically signif-
icant improvement in average sensitivity and specificity (Table 2).
Patient-by-patient comparison of the CA 19–9 assays
The above analysis shows that CA 19–9 performance is similar between Assay 1 and Assay 2
when evaluated over all patients, but we also wanted to know how the two assays compared for
individual patients. A direct comparison of the values obtained for each patient showed major
differences for certain patients (Fig 2). The discrepancies between the assays were evenly dis-
tributed; in some cases Assay 1 was higher, and in other cases Assay 2 was higher.
At a practical level, discrepancies between the assays only matter in relation to the cutoffs
used in clinical practice. Therefore we queried how often the status of a sample was different
between Assay 1 and Assay 2 in relation to the cutoff (Table 3). Using 37 U/mL as the cutoff, 8
of the 53 cancer patients (15%) elevated in Assay 1 were low in Assay 2, and 7 of the 52 cancer
patients (14%) elevated in Assay 2 were low in Assay 1. Seven of the 128 control subjects (5%)
not elevated in Assay 1 were elevated in Assay 2, and 9 of the 130 controls (7%) not elevated in
Assay 2 were elevated in Assay 1. Discrepancies also were present using a 100 U/mL cutoff.
Thus, although the two assays give generally the same overall performance, differences were
apparent for individual patients. Each assay occasionally gave false negative or false positive
results as compared to the other.
Testing the CA 19–9 assays in combination
We evaluated whether a combination of the two assays gave better results than either assay
alone. This concept is based on the premise that if the antibodies in each assay optimally detect
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distinct subsets of patients, a greater percentage of patients would be detected if the assays were
combined. We used logistic regression to derive linear combinations of the log-transformed
values of the two assays, and evaluated the AUCs for separating cancer from each of the control
groups based on the combined score. Combining the two assays did not show significant
improvement for distinguishing cancer from the healthy or the chronic pancreatitis groups
(Fig 1 and Table 2). In addition, using simple combination rules based on AND or OR opera-
tors, at either optimized cutoffs or the standard 37 U/mL cutoff, there was minimal improve-
ment in average sensitivity and specificity relative to the individual assays (Table 2). Therefore,
although the two assays potentially identify non-overlapping sets of patients (as suggested by
the lack of perfect correlation in Fig 2), they do not contribute complementary, cancer-specific
information.
Specificity differences between the CA 19–9 antibodies
More information about the origin of the differences between the assays could be helpful to
optimize the detection of cancer patients while minimizing detection of control subjects. The
antigen nominally recognized by CA 19–9 antibodies is a glycan called sialyl Lewis A [16], with
the sequence Siaα2,3Galβ1,3(Fucα1,4)GlcNAc, where Sia is sialic acid, Gal is galactose, Fuc is
fucose, and GlcNAc is N-acetylglucosamine. Sialyl Lewis A is a member of the Lewis blood
group system of glycans on red blood cells and a variety of glycoproteins and glycolipids [22,
28]. Although sialyl Lewis A is the main glycan bound by CA 19–9 antibodies, other glycans
may be bound [19, 29]. A powerful tool for getting more information about what other glycans
an antibody binds is the glycan array [24, 30], which enables measurements of the binding of a
protein to many different glycans in parallel. We therefore obtained glycan array data for the
antibodies used in Assays 1 and 2.
Table 2. Marker performance at selected cutoffs.
Markers AUC(95%CI) Marker Cutoff (U/
mL)
Sensitivity (95%CI) Speciﬁcity (95%CI) (Sens+Spec)/2 (95%CI)
Assay 1 Assay 2
All cancer vs. healthy subjects
Assay 1 –optimized cutoff 0.78 (0.70–0.84) 23.165 66.3 (54.1–77.6) 90.2 (82.0–98.4) 78.2 (73.3–84.3)
Assay 1 –clinical cutoff 37 54.1 (43.9–63.8) 95.1 (88.5–100.0) 74.6 (68.6–80.4)
Assay 2 –optimized cutoff 0.76 (0.68–0.83) 16.64 75.5 (57.6–83.7) 75.4 (67.2–92.7) 75.5 (70.1–82.1)
Assay 2 –clinical cutoff 37 53.1 (42.9–62.2) 88.5 (80.3–95.1) 70.8 (64.7–76.8)
AND–optimized cutoffs 22.00 14.05 65.3 (56.6–81.1) 91.8 (77.0–100.0) 78.6 (74.0–84.7)
OR–optimized cutoffs 23.40 170.85 67.3 (56.1–82.7) 90.2 (75.4–98.4) 78.8 (74.5–84.9)
AND–clinical cutoffs 37 37 45.9 (35.7–56.1) 95.1 (88.5–100.0) 70.5 (64.9–76.0)
OR–clinical cutoffs 37 37 61.2 (50.0–70.9) 88.5 (80.3–95.1) 74.9 (68.9–80.8)
All cancer vs. chronic pancreatitis
Assay 1 –optimized cutoff 0.73 (0.65–0.80) 29.78 61.2 (43.9–75.5) 82.3 (71.0–96.8) 71.7 (67.3–79.6)
Assay 1 –clinical cutoff 37 54.1 (43.9–65.3) 87.1 (79.0–95.2) 70.6 (64.0–77.3)
Assay 2 –optimized cutoff 0.77 (0.69–0.83) 25.25 65.3 (54.1–78.6) 87.1 (74.2–96.8) 76.2 (70.6–82.4)
Assay 2 –clinical cutoff 37 53.1 (42.9–63.3) 91.9 (83.9–97.6) 72.5 (65.8–78.6)
AND–optimized cutoffs 0.0 25.66 65.3 (52.0–76.5) 87.1 (79.0–97.6) 76.2 (71.8–83.1)
OR–optimized cutoffs 42.00 25.66 68.4 (56.1–78.6) 85.5 (77.4–95.2) 76.9 (72.2–83.4)
AND–clinical cutoffs 37 37 45.9 (35.7–56.1) 95.2 (88.7–100.0) 70.5 (64.4–76.2)
OR–clinical cutoffs 37 37 61.2 (51.0–71.4) 83.9 (74.2–91.9) 72.5 (65.6–79.1)
doi:10.1371/journal.pone.0139049.t002
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Both antibodies bound the canonical CA 19–9 antigen—sialyl Lewis A—but with differ-
ences (Fig 3 and Fig 4). The antibody from Assay 2 (9L426) bound more strongly than the
Assay 1 antibody to dimeric sLeA-LeA, as evidenced by the better signal at the low concentra-
tion of 0.2 μg/mL, but it showed no binding to the sialic acid variant Neu5Gc. It also bound to
sialyl Lewis C (non-fucosylated sialyl Lewis A) at the relatively high concentration of 20 μg/
mL. In contrast, the Assay 1 antibody (only the detection antibody was available from the
Fig 2. Correlation between Assay 1 and Assay 2. The log-transformed CA 19–9 values of all subjects from
Assay 1 and Assay 2 were plotted with respect to each other. Each circle indicates an individual patient
sample. The trendline is the linear-least squares best fit, and the Spearman’s rank correlation coefficient is
0.74.
doi:10.1371/journal.pone.0139049.g002
Table 3. Deviations between the assays at specific cutoffs.
Cancer Patients Control Subjects
Assay 2 Assay 2
37 U/mL Low High 37 U/mL Low High
Assay 1 Low 38 7 Assay 1 Low 121 7
High 8 45 High 9 17
Cancer Patients Control Subjects
Assay 2 Assay 2
100 U/mL Low High 100 U/mL Low High
Assay 1 Low 68 2 Assay 1 Low 139 5
High 4 24 High 4 6
doi:10.1371/journal.pone.0139049.t003
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commercial kit) showed greater binding to Neu5Gc but no additional binding to sLeC. A third
antibody (clone M081221, Fitzgerald, Acton, MA), not used in Assay 1 or 2 but included for
comparison, bound other glycans in addition to those displaying the canonical CA 19–9 anti-
gen. This antibody cross-reacted with glycans containing sialyl Lewis X, an isomer of sialyl
Lewis A in which the attachment of the fucose and galactose to the core structure is switched.
Thus the CA 19–9 antibodies have overlapping but distinct specificities, including binding to
some structures beyond the canonical CA 19–9 antigen.
Fig 3. Glycan array analysis of three CA 19–9 antibodies. Each antibody was incubated at 2 μg/mL on a glycan array containing 610 distinct glycans
(glycan array version 5.1 from the Consortium for Functional Glycomics). The graph includes the glycans showing the highest levels of binding by any of the
antibodies. For each antibody, we normalized the raw fluorescence values to set the highest value to 1. The list specifies the glycans included in the plot, and
the labels above the columns indicate the primary motif in each glycan. DRG is the Assay 1 antibody, 9L426 is the Assay 2 antibody, and M081221 is another
anti-sialyl Lewis A antibody included for comparison.
doi:10.1371/journal.pone.0139049.g003
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Discussion
The reference set presented here is intended to facilitate reliable and rapid assessment of the
performance of candidate biomarkers for the detection of pancreatic cancer. The large cohort
of resectable pancreatic cancer, the furnishing of samples from multiple institutions using a
standard procedure, and the inclusion of chronic pancreatic and benign biliary obstruction
control groups establish the value of the set for validating assays. A first step in using the refer-
ence set was to characterize the performance of the CA 19–9 assay, in order to provide a bench-
mark for subsequent candidate biomarkers, to give a definitive evaluation of CA 19–9 in
resectable pancreatic cancer, and to enable assessments of the combined use of candidate bio-
markers and CA19-9. The use of two assays for CA 19–9 provided additional details about the
Fig 4. Glycanmotifs recognized by three CA 19–9 antibodies. For each antibody, the binding intensity to the indicated glycans, in relative fluorescence
units, is given at three antibody concentrations (in μg/mL). Green indicates strong binding, yellow is moderate binding, and pink is weak binding.
doi:10.1371/journal.pone.0139049.g004
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biomarker, namely that subtle differences in specificity can affect results for individual patients
but not necessarily for overall statistics.
The cohort of stage I-II pancreatic cancer patients in the reference set is substantially larger
than what is typically available for pancreatic cancer biomarker studies, so the results presented
here likely provide the most reliable information currently available about CA 19–9 in stage
I-II pancreatic cancer. The main reason for the lack of large studies on early-stage pancreatic
cancer has been the difficulty in obtaining the samples. Typical biomarker studies in pancreatic
cancer include a small minority of stage I/II patients, such as a study in which 10 of the 67 pan-
creatic cancer patients had stage I/II disease [31]. Many studies do not specify the stage of the
patients but likely involve mostly late stage patients because samples from late-stage patients
are more readily available. The performance of CA 19–9 observed here using only stage I-II
cases is comparable to that of previous studies using a mix of stages [17]. A review of 22 differ-
ent studies of CA 19–9 for the diagnosis of pancreatic cancer reported 79% sensitivity and 82%
specificity, averaged over all studies [17]. Previous studies found increases in average CA 19–9
levels with tumor stage and tumor size [21, 32–34]. The sensitivities were 40%, 68%, and 89%
for T1 (tumor< 2 cm), T2 (< 2 cm and> 4 cm), T3 (> 4 cm), respectively [32]. Our determi-
nation of sensitivity at 54% for stage I-II cancer at the clinical cutoff of 37 U/mL (Table 2) is
consistent with these findings. Taken together, our results show that many small, organ-con-
fined cancers secrete appreciable levels of CA 19–9 antigen into the blood, and that a portion
of pancreatic cancers does not secrete CA 19–9 even at later stages. The discovery of markers
that are complementary to CA 19–9 is needed to detect the full spectrum of pancreatic cancers.
Samples from chronic pancreatitis patients were included because of known difficulties in
distinguishing this condition from pancreatic cancer. Chronic pancreatitis patients did not
show elevations in CA 19–9 relative to the healthy control subjects. Other studies have found
elevations above 37 U/mL in 18–21% of patients with chronic pancreatitis [32, 33]. The vari-
ance between the results of our study and those of some previous studies may be due to differ-
ences in the selection of the chronic pancreatitis patients, for example due to greater care in
this study to select confirmed chronic pancreatitis patients in a quiescent state. In any case, the
observations of higher CA 19–9 levels in cancer relative to chronic pancreatitis have led some
to suggest the use of higher thresholds (>100 U/mL) for the differential diagnosis of pancreatic
cancer from chronic pancreatitis [31, 32, 34, 35]. Our study confirmed that elevations can be
confirmatory for stage I-II pancreatic cancer with a sensitivity of ~70% at thresholds that give
near perfect specificity. Therefore CA 19–9 can provide very reliable confirmatory information,
but only for the subset of patients with moderate and greater elevations.
We included samples from patients with benign biliary obstruction—defined as biliary
obstruction in the absence of pancreatitis or pancreatic cancer—to gather more information
about the sources of biomarker elevation, since masses in the pancreas arising from cancer or
pancreatitis can cause biliary obstruction. The present study agreed with previous studies
showing that biliary obstruction can cause elevations in CA 19–9 nearly equivalent to those of
early-stage pancreatic cancer [36, 37]. This fact has led to speculation that the elevations of CA
19–9 in all pancreatic diseases are simply a secondary effect from biliary obstruction, rather
than due to secretions from the pancreatic parenchyma. Several lines of evidence suggest other-
wise. Pancreatic cancer patients without jaundice often have CA 19–9 elevations; some cancer
patients continue to have elevated CA 19–9 even after the relief of biliary obstruction; and
immunohistochemical analysis of CA 19–9 in pancreatic cancer show thick perfusion of the
cancerous tissue with CA 19–9, showing direct secretion from the cancer cells. Therefore, in
cases where biliary obstruction is not present or has been resolved, CA 19–9 elevations in the
serum likely result directly from cancer cell secretions. Future studies using the reference set
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should benefit from a similar analysis of benign biliary obstruction cases, especially considering
that jaundice is a known source of non-specific elevation for some protein biomarkers [38].
The comparison of CA 19–9 assays has implications for interpretation of the values. The
two assays agreed very well in their summary statistics and overall trends, but the values did
not always agree for individual patients (Fig 2), in some cases leading to differences in status
relative to the 37 U/mL or 100 U/mL cutoffs (Table 3). We conclude that the interpretation
and comparison of CA 19–9 values should always take into account the assay used. This find-
ing is consistent with previous research showing divergence between CA 19–9 assays [27] and
a previous study linking that divergence to the glycan-binding characteristics of the antibodies
[19].
A previous study examined the binding of 20 different monoclonal antibodies against sialyl
Lewis A to 9 different glycan structures [39]. The study agreed with our results in finding varia-
tion between the antibodies (none of the 20 were in our study), but it did not include several
important glycans similar to sialyl Lewis A, such as sulfated glycans, sialyl Lewis C, and Lewis
Y, and it provided no information about the effects of branching or extension. The glycan
arrays used in the present study contained over 600 glycans, including glycans similar to sialyl
Lewis A and unrelated glycans that serve as negative controls. Therefore we have a higher level
of detail in the analysis of the specificities of the antibodies, which can serve to better interpret
results obtained using the antibodies.
Other factors in addition to specificity differences could contribute to differences between
the assays, such as precision and interference from heterophile antibodies. It is likely that such
factors contributed to discrepancies, but there is evidence for a major contribution from speci-
ficity differences. The differences between assays for selected samples shown by the scatter plot
of Fig 2 are larger than the imprecision in the assays, and because all antibodies were mouse
monoclonals, heterophile interference likely would be similar between the assays. Future exper-
iments also could delve into this question more deeply. One could characterize the glycans of
samples that show major differences between the assays to determine whether particular glycan
motifs were detected preferentially by one assay relative to the other.
In summary, we describe a resource for pancreatic cancer biomarker development and the
use of this resource to advance our knowledge about the CA 19–9 test. The reference set has
several features that make it ideal for biomarker testing, including a large cohort of resectable
cancers, samples from multiple institutions, and the inclusion of the key control groups. The
value of using a common sample set was demonstrated by the use of two assays for CA 19–9, as
they agreed in their summary statistics but were divergent for individual patients. The refer-
ence set promises to be a valuable resource for biomarker validation and comparison, and
future studies of candidate biomarkers in the reference set could be compared and integrated
with the present results.
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